Tayo Sanders

Company: Singular Immune

Job title: Chief Business Officer

Bio:

Dr. Tayo Sanders II is Chief Business Officer at Singular Immune, where he leads strategic partnerships and business development for in vivo cell engineering therapies. A Rhodes Scholar with a PhD from the University of Oxford, he brings a strong foundation in science and entrepreneurship. Prior to Singular Immune, Tayo held roles at CytoTronics, Station 41, and Anzu Partners, contributing to early-stage biotech innovation. He is a frequent speaker on the intersection of science, business, and innovation, with a passion for advancing transformative therapeutic technologies. 

Seminars:

Analyzing In Vivo Approaches, Delivery & Safety to Uncover their Future Potential 3:10 pm

Exploring the therapeutic potential of in vivo approaches, including in vivo and B-cell depletion to anticipate a future developments Assessing if the rules that govern cancer therapies are applicable to autoimmunity to effectively evaluate knockout strategies with lentiviral vectors or opportunities for redosing with mRNA Debating safety versus efficacy in the context of LNP and…Read more

day: Day One